Lipaikin Sergei, Dorokhin Aleksei, Ryltseva Galina, Oberenko Andrey, Kiselev Evgeniy, Shabanov Alexander, Volova Tatiana, Shishatskaya Ekaterina
Siberian Federal University, 79 Svobodny pr., Krasnoyarsk 660041, Russia.
Institute of Biophysics SB RAS, Federal Research Center "Krasnoyarsk Science Center SB RAS", 50/50 Akademgorodok, Krasnoyarsk 660036, Russia.
ADMET DMPK. 2024 Oct 9;12(6):925-942. doi: 10.5599/admet.2434. eCollection 2024.
Cyclophosphamide (CP) is a widely used antitumor and immunosuppressive drug, but it is highly cytotoxic and has carcinogenic and teratogenic potential. To reduce adverse effects of CP therapy and the frequency of its administration, the microencapsulation of CP into biodegradable polymeric matrices can be performed. However, according to the literature, only a few polymers were found suitable to encapsulate CP and achieve its' sustained release.
In this research, spray-dried cyclophosphamide-loaded poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) microparticles were prepared and characterized in terms of their average hydrodynamic diameter, polydispersity index, surface morphology, zeta potential, encapsulation efficiency, drug loading, thermal properties and cytotoxicity against 3T3 cells.
The obtained CP-loaded microparticles had a regular spherical shape, uniform size distribution with an average diameter of 4.21±0.04 μm and zeta potential of -34.2±0.2 mV. The encapsulation of cyclophosphamide into the PHBV matrix led to a decrease in melting and degradation temperatures and an increase in diameter, glass transition and cold crystallization temperatures compared to blank microparticles. Moreover, microencapsulation of cyclophosphamide lowered its cytotoxicity compared to the pure drug: the number of dead cells in the culture decreased by 28 %, while their metabolic activity increased by 20 %. The cumulative drug release studies showed a gradual release of CP up to 18 days, so the obtained microparticle formulation can be used as a sustained-release cyclophosphamide delivery system.
In this research, a novel cyclophosphamide-loaded platform based on PHBV microparticles was established and characterized. Overall, this study offers promising prospects for cancer therapy in the future.
环磷酰胺(CP)是一种广泛应用的抗肿瘤和免疫抑制药物,但具有高细胞毒性以及致癌和致畸潜能。为降低CP治疗的不良反应及其给药频率,可将CP微囊化于可生物降解的聚合物基质中。然而,据文献报道,仅发现少数几种聚合物适合包封CP并实现其缓释。
本研究制备了喷雾干燥的载环磷酰胺聚(3-羟基丁酸酯-co-3-羟基戊酸酯)(PHBV)微粒,并对其平均流体动力学直径、多分散指数、表面形态、zeta电位、包封率、载药量、热性质以及对3T3细胞的细胞毒性进行了表征。
所制备的载CP微粒呈规则球形,尺寸分布均匀,平均直径为4.21±0.04μm,zeta电位为-34.2±0.2mV。与空白微粒相比,环磷酰胺包封于PHBV基质中导致熔点和降解温度降低,而直径、玻璃化转变温度和冷结晶温度升高。此外,与纯药物相比,环磷酰胺的微囊化降低了其细胞毒性:培养物中死细胞数量减少了28%,而其代谢活性增加了20%。累积药物释放研究表明,CP可持续释放长达18天,因此所获得的微粒制剂可作为环磷酰胺缓释给药系统。
本研究建立并表征了一种基于PHBV微粒的新型载环磷酰胺平台。总体而言,本研究为未来癌症治疗提供了有前景的方向。